Literature DB >> 12604315

T-cell function in anti-GAD65(+)diabetes with residual beta-cell function.

Ryuji Suzuki1, Akira Shimada, Taro Maruyama, Osamu Funae, Jiro Morimoto, Keiichi Kodama, Yoichi Oikawa, Akira Kasuga, Koichi Matsubara, Takao Saruta, Shosaku Narumi.   

Abstract

We have recently reported that in patients with anti-glutamic acid decarboxylase (GAD) 65(+)diabetes with residual beta-cell function, most with a 'high-titer' (>10U/ml) required insulin within 5 years, whereas most with a 'low-titer' (1.3-9.9U/ml) did not need insulin for over 15-20 years after the onset. We therefore examined T-cell function to evaluate the difference between the high-titer and low-titer groups. Interleukin (IL)-10 production upon polyclonal activation was significantly lower in the high-titer group than in the low-titer group. The serum level of interferon-inducible protein-10 (IP-10) was higher in the high-titer than the low-titer group. Although GAD65-reactive CD4(+)cells in the periphery were detected in both groups, a significant positive correlation between serum IP-10 level and the number of GAD65-reactive CD4(+)cells was observed only in the high-titer group. Therefore, it has been speculated that the co-existence of GAD65-reactive IFN-gamma-producing CD4(+)cells and a high serum IP-10 level may be important for rapid disease progression as seen in the high-titer group. Based upon these results, T-cell function is considered to be different between the high-titer and low-titer groups in anti-GAD65(+)diabetes with residual beta-cell function, supporting our previous findings regarding the clinical outcome of insulin-dependence in the two groups.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12604315     DOI: 10.1016/s0896-8411(02)00093-8

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  4 in total

1.  CXC chemokine ligand 10 DNA vaccination plus Complete Freund's Adjuvant reverses hyperglycemia in non-obese diabetic mice.

Authors:  Yoichi Oikawa; Akira Shimada; Yoshifumi Yamada; Yoshiaki Okubo; Takeshi Katsuki; Toshikatsu Shigihara; Jun-Ichi Miyazaki; Shosaku Narumi; Hiroshi Itoh
Journal:  Rev Diabet Stud       Date:  2010-11-10

Review 2.  CXCL10 activities, biological structure, and source along with its significant role played in pathophysiology of type I diabetes mellitus.

Authors:  Zahra Ahmadi; Mohammad Kazemi Arababadi; Gholamhossin Hassanshahi
Journal:  Inflammation       Date:  2013-04       Impact factor: 4.092

3.  The role of the CXCL10/CXCR3 system in type 1 diabetes.

Authors:  Akira Shimada; Yoichi Oikawa; Yoshifumi Yamada; Yoshiaki Okubo; Shosaku Narumi
Journal:  Rev Diabet Stud       Date:  2009-08-10

4.  Predictive value of titer of GAD antibodies for further progression of beta cell dysfunction in slowly progressive insulin-dependent (type 1) diabetes (SPIDDM).

Authors:  Shoichiro Tanaka; Minoru Okubo; Kaoru Nagasawa; Soichi Takizawa; Masashi Ichijo; Sayaka Ichijo; Masahiro Kaneshige; Kaoru Aida; Hiroki Shimura; Yasumichi Mori; Tetsuro Kobayashi
Journal:  Diabetol Int       Date:  2015-05-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.